Interview with Safia Rizvi, Managing Director, UCB India
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Address: 504, Peninsula TowersPeninsula Corporate ParkGanpatrao Kadam Marg, Lower ParelIND – Mumbai 400 013,India
Tel: +91 22 40 49 11 11
Web: http://www.ucb.com/india/
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Vimpat® (lacosamide)
Epilepsy
Keppra® (levetiracetam)
Epilepsy
Neupro® (rotigotine)
Parkinson’s disease
Restless Legs Syndrome
Nootropil® (piracetam)
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol)
Crohn’s disease
Rheumatoid arthritis
Xyzal® (levocetirizine)
Allergies
Zyrtec® (cetirizine)
Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
Respiratory disease
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
Satish Kumar Singh (managing director) & Shashi Shekhar Kumar (vice president International Business) from M/s Cachet Pharmaceuticals Pvt. Ltd., discuss their success with special reference to marketing, distribution and operating…
A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Kiran Mazumdar-Shaw, discusses the recent US FDA approval of Ogivri™, the first biosimilar…
A nationwide renowned neonatologist and member of the High Level Expert Group on Universal Health Coverage, NITI Aayog’s medical expert, Dr. Vinod K. Paul introduces the work that the government…
Newly appointed commissioner of the Food & Drugs Administration (FDA) of the Indian state of Maharashtra, Dr. Pallavi Darade, shares her objectives to further consolidate the FDA’s positioning as a…
With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to the country’s vast population, two pioneering pharmaceutical multinationals – Novartis and Janssen –…
Kanchana TK, director general of the Organisation of Pharmaceutical Producers of India (OPPI), the association which represents the interests of research-based pharmaceutical companies in India, discusses regulatory reform and how…
Janmejay Vyas, chairman of the Dishman Group, shares the story of his success in establishing a trustworthy relationship with the strictest drug regulator in the world, the US FDA. Mr…
See our Cookie Privacy Policy Here
